Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic discovers potential marker for aggressive kidney cancer

01.12.2004


New help for tailoring treatments

Mayo Clinic researchers have discovered a key molecule that lets doctors identify one of the most aggressive types of kidney cancer. Patients with renal cell carcinoma who have higher levels of a molecule known as B7-H1 in their tumors are nearly five times more likely to die from the disease than patients with low levels or an absence of the molecule.

This key finding can help to improve treatment of the disease, or to serve as a target for new therapies. The findings are published in today’s online issue of the Proceedings of the National Academy of Sciences, http://www.pnas.org.



Significance of the Mayo Clinic Research

  • This is the first time this molecule has been demonstrated to be expressed on kidney cancers. Prior to the Mayo Clinic investigation researchers knew that B7-H1 is usually found on immune cells and is found in some other cancers, but is not found on the healthy kidney.
  • When B7-H1 is expressed, it shuts down the immune system, limiting the body’s ability to attack the tumor and perhaps increasing a tumor’s ability to grow and spread.
  • This is the first time that this kind of molecule has been correlated with clinical cancer progression and risk of death.

"Many people have hypothesized that if a cancer makes B7-H1, that cancer may be more aggressive because B7-H1 knocks down the host’s immune system, thereby permitting the tumor to grow without interference from the immune system," explains Eugene Kwon, M.D., the immunologist and urologist who led the study. "But there has been no evidence at the clinical level to demonstrate tumors that express B7-H1 are aggressive, so there’s been no way to prove this hypothesis."

Dr. Kwon’s group studied 196 samples from kidney tumors of patients treated at Mayo Clinic. They found that when patients express this molecule on their kidney cancer cells, they are at markedly increased risk both of the cancer spreading, and of dying from the cancer. "We found that when you have high levels of this molecule, your risk of dying from this cancer goes up almost five-fold," Dr. Kwon says.

Implications of Research

This molecule seems suited to be used as a biomarker by physicians to determine prognosis, according to the Mayo researchers. High levels of the molecule would indicate a poor prognosis, while low levels or its absence would suggest a good prognosis. The level of this molecule could also be used to help select the most effective treatments. For example, it’s possible that patients with high levels of B7-H1 may be the best candidates for immunotherapeutic treatment using agents such as Interleukin-2 (IL-2) and alpha interferon.

Furthermore, say the researchers, a drug developed to block B7-H1 could theoretically be created to improve the effectiveness of immunotherapy. For instance, an antibody could be developed that would bind B7-H1 and block its function. By doing so, either alone or in combination with standard therapy, this would potentially improve treatment responses of patients with kidney cancers by protecting their immune system from being shut down.


About Kidney Cancer

There are different kinds of kidney cancers. Renal cell carcinoma accounts for approximately 85 percent of all kidney cancers. In the United States, an estimated 35,000 patients will be diagnosed with kidney cancer and approximately 12,000 will die from this disease every year. It is the eighth most common cancer in men and the 10th most common cancer in women. In the United States, it is the sixth leading cause of cancer death.

The primary treatment for advanced kidney cancer -- Interleukin 2 -- has significant limitations. It is relatively toxic, can further sicken the patient and only elicits a response in 15-20 percent of all patients treated. This means 80-85 percent of patients are not significantly helped by it, but nonetheless exposed to its toxicity.

"That’s why we’re so interested in this molecule," says Dr. Kwon. "We think that by recognizing that B7-H1 may be an immune-suppressive molecule, we might be able to make patients much more receptive or responsive to immunotherapy using either IL-2 or some of the other agents that are out there just by manipulating B7-H1 appropriately. We could improve treatment outcomes, hopefully, and that’s what’s drastically needed for this disease."

Bob Nellis | EurekAlert!
Further information:
http://www.mayo.edu
http://www.pnas.org

More articles from Health and Medicine:

nachricht Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Graphene assembled film shows higher thermal conductivity than graphite film

22.06.2018 | Materials Sciences

Fast rising bedrock below West Antarctica reveals an extremely fluid Earth mantle

22.06.2018 | Earth Sciences

Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View

22.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>